Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , April 21, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of its previously announced underwritten public offering of 69,000,000 shares of its common stock, including 9,000,000 shares sold pursuant to the full exercise of an option
View HTML
Toggle Summary Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , April 17, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 60,000,000 shares of its common stock, offered at a price to the public of $1.15 per share.  The gross proceeds from the offering are expected to
View HTML
Toggle Summary Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , April 17, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Arena expects to grant the underwriters a 30‑day option to
View HTML
Toggle Summary Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology
- Data to highlight etrasimod, Arena's orally available next generation sphingosine-1-phosphate (S1P) receptor modulator for the potential treatment of autoimmune diseases -
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference on April 4th
SAN DIEGO , March 27, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced that Amit Munshi , the Company's President and Chief Executive Officer, will present
View HTML
Toggle Summary Arena Pharmaceuticals Appoints Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer
SAN DIEGO , March 20, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced the appointment of Dr. Preston Klassen , M.D., M.H.S.
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 27th Annual Oppenheimer Healthcare Conference
SAN DIEGO , March 8, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced that Amit Munshi , the Company's President and Chief Executive Officer will present
View HTML
Toggle Summary Arena Pharmaceuticals Appoints Three New Members to Board of Directors
SAN DIEGO , Feb. 14, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the appointment of three new members to the company's Board of Directors.  Jayson Dallas , M.D., Oliver Fetzer , Ph.D., and Garry A. Neil , M.D. have joined as independent directors.  The new
View HTML
Toggle Summary Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2017
SAN DIEGO , Feb. 9, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Dr. Scott Lee and Professor Tanja Kühbacher will present data on etrasimod (APD334) at the 12th Congress of European Crohn's and Colitis Organisation (ECCO) - Inflammatory Bowel Diseases 2017
View HTML
Toggle Summary Arena Pharmaceuticals and Eisai Amend Marketing and Supply Agreement for BELVIQ Globally
Arena Expects to Receive $23 Million of Cash Payments and Over $80 Million of Potential Cost Relief and Will Continue to Focus on Its Clinical Programs
View HTML